The FDA just released draft guidance on decentralized clinical trials (DCTs). Our clinical science and trial optimization experts provide a summary of its key themes and offer perspective in this white paper. You’ll learn about:

• Applications for technology in DCTs
• Considerations for investigator oversight
• Preserving data precision and integrity

Read the paper to find out how this guidance might inform your next study.